SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Ian@SI who wrote (2010)1/6/2004 5:30:18 PM
From: Miljenko Zuanic  Read Replies (1) of 3044
 
What about NSCLC, PC, Ovarian, H&N,...???

Those were Irino refractory pts, and point was to observe could Velcade re-sensitize this population for Irino, as third line therapy. Similar to what IMCL did done with C225 (and they did try to cheat with Irino-stable!!!). Fact they Velcade didn’t have efficacy here does not say anything about overall (or specific) activity in solid tumor. BTW, Irino refractory and metastatic (after Irino second line failure) is one of the hardest CRC-indication.

Miljenko
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News